A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
Clinical trial NCT02526979 · COMPLETED
Trial details
- NCT number
- NCT02526979
- Sponsor
- Astellas Pharma Europe B.V.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-17
- Primary completion
- 2016-09-30
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.